- AdventHealth
“This new consensus statement is of critical importance as the number of people with metabolic dysfunction associated steatotic liver disease (MASLD) is on the rise. Many health care professionals have limited knowledge on how to best help people with diabetes who are at risk of liver disease, and our panel wanted to help bridge this knowledge gap.” -- Karen D. Corbin, PhD, RD, AdventHealth Translational Research Institute (TRI)
MASLD, formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality.
AdventHealth TRI’s Dr. Karen Corbin served on a panel of leading experts from across the country who developed and recently released the first American Diabetes Association (ADA) consensus statement on liver disease in people with type 2 diabetes. It emphasized the need for screening and early intervention to slow disease progression and improve outcomes.
Recent News
Melissa’s Race Continues to Advance Brain Cancer Research
The AdventHealth community was honored to once again join supporters, families and advocates at Melissa’s Race to Battle Brain Cancer — a meaningful event that continues to inspire hope and advance...
Bringing Cancer Research Into the Home: Dr. Justin Brown's Approach to Trial Design
Justin Brown, PhD, Associate Investigator at AdventHealth, has dedicated his career to studying how exercise can improve outcomes for cancer patients after losing his father to colon cancer as a...
Exercise as “Powerful Medicine”: Spotlight on AdventHealth Research
Recently, Dr. Bret Goodpaster, scientific director of the AdventHealth Translational Research Institute (TRI), appeared on FOX 35 News to discuss groundbreaking research exploring how exercise impacts...
New Study Points to Promising Way to Protect Kidneys in Type 1 Diabetes
Richard E. Pratley, M.D., senior investigator and diabetes program lead at the AdventHealth Translational Research Institute (TRI), served as one of the lead researchers on the international FINE-ONE...
Understanding Hypoglycemia and the CLEAR Study
The CLEAR Study is a groundbreaking, international research effort funded by the NIH that aims to help people with Type 1 diabetes (T1D) who can no longer sense when their blood sugar is dangerously...
Recognizing the Unrecognized: Advancing Research in Childhood Sjögren’s Disease
Sjögren’s disease has been recognized in adults for almost a century, first described by Swedish ophthalmologist Henrik Sjögren in the early 20th century. One of the biggest challenges in recognizing...
Did you know? Women, Hormones, and Heart Risk
Heart disease is often thought of as a “man’s disease,” but it remains the leading cause of death for women in the United States. We asked Katie Love, MD, MSc, an investigator at the AdventHealth...
Weight-Loss Drugs, Hormones, and Midlife: What Women Need to Know
Understanding the connection between GLP-1 medications and hormone therapy
Women, Brain Health, and the Alzheimer’s Puzzle
Why scientists are taking a closer look at why women face higher Alzheimer’s risk
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.